cdk-9-in-1

CDK9-IN-1 是一种具有选择性和高效性的 CDK9 抑制剂，具有抗病毒活性，用于研究 PRRSV 感染。

CDK9-IN-10 是一种有效的 CDK9 抑制剂。CDK9-IN-10 是 PROTAC CDK9 degrader-2 的配体。

CDK9-IN-15 是一种有效的小分子CDK9抑制剂，可通过降解、抑制 CDK9 来阻断正性转录延长因子 P-TEFb (positive transcription elongation factor b) 对 RNA Poly-II C末端区域的磷酸化，抑制转录，迅速降低细胞内 mRNA 水平，从而引起肿瘤细胞凋亡。

CDK9-IN-11 是一种有效的CDK9抑制剂，可作为 PROTAC CDK9 Degrader-1 的配体。

CDK9-IN-12 是一种高选择性的 CDK9 抑制剂，通过 靶向 CDK9 依赖的转录过程，调控 癌基因的表达并抑制癌细胞的增殖并诱导细胞凋亡，常用于研究白血病。

EGFR HER2 CDK9-IN-1 (Compound 4) 是一种有效的 EGFR HER2 CDK9 抑制剂，他们的 IC50 值分别为 90.17、131.39 和 67.04 nM。EGFR HER2 CDK9-IN-1 表现出明显的抗肿瘤作用。

CDK9-IN-18 是一种 CDK9 的有效抑制剂，能够阻断激酶 CDK9 的磷酸化功能。CDK9-IN-18 表现出良好的抗癌活性和低细胞活性，并能够诱导细胞凋亡。

A09-003 是一种新型细胞周期蛋白依赖性激酶-9 CDK-9 抑制剂。A09-003 能够抑制多种白血病细胞系的增殖，抑制hi髓系细胞白血病序列-1蛋白增加。A09-003还能诱导细胞凋亡，降低 RNA 聚合酶 II 活性，降低 Mcl-1 表达。

CKD-712 is a nuclear factor NF-kappa B inhibitor. CKD-712 suppressed MMP-9, but not MMP-2 and other NF-κB-regulated proteins involved in cancer metastasis such as VEGF. CKD-712 induced cell cycle arrest at G2M phase by suppressing cyclin A, cyclin B and C

CDK6 9-IN-1 (compound 66) is a potent dual inhibitor of CDK 6 and CDK 9 that can be administered orally. It exhibits inhibitory activity with IC 50 values of 40.5 nM and 39.5 nM against CDK6 and CDK9, respectively.

CDK7 9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7 9 (CDK7 9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7 9-IN-1 demonstrates excellent inhibitory potency against CDK7, with IC50 values of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. Furthermore, CDK7 9-IN-1 inhibits CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation. Its application in cancer research makes it valuable for such investigations.

CDK7-IN-16 (compound 9) 是一种 CDK 7 的有效抑制剂 (IC50: 1-10 nM)。CDK7-IN-16 能够用于研究抗癌，特别是转录异常的癌症。

Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7 cyclin H Mat1 and Cdk9 cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibulocydine rapidly blocked phosphorylation of the carboxyl-terminal domain (CTD) of the large subunit of RNA polymerase II, a process mediated by Cdk7 9. Anti-apoptotic gene products such as Mcl-1, survivin, and X-linked IAP (XIAP) are crucial for the survival of many cell types, including HCC. Following the inhibition of RNA polymerase II phosphorylation, ibulocydine caused rapid down-regulation of Mcl-1, survivin, and XIAP, thus inducing apoptosis. Furthermore, ibulocydine effectively ind......

CDK4 6-IN-14 是一种有效且高度选择性的 CDK4和 CDK6(CDK) 抑制剂，IC50分别为 10 nM 和 16 nM。CDK4 6-IN-14 的选择性是 CDK1、2、7 和 9 的 60 多倍，并且在其他 205 种激酶中表现出高选择性。

CDK2-IN-26（化合物9）表现为对CDK2的高效抑制作用。